Pembrolizumab

SEP 8, 2026 · PHASE 1/2 TRIAL

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

ClinicalTrials.gov

This is a first-in-human, Phase 1/2 open-label dose escalation and expansion study with no results yet posted; only design and planned enrollment are available.

SEP 8, 2026 · PHASE 3 TRIAL

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

ClinicalTrials.gov

This is a clinical trial registry record describing a planned Phase 3 study with no results reported; it documents study design and enrollment targets only.

SEP 8, 2026 · PHASE 1 TRIAL

Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

ClinicalTrials.gov

This is a first-in-human Phase 1 trial registration with no results posted; the study is not yet recruiting and therefore represents early-stage, pre-clinical development work.

SEP 8, 2026 · PHASE 3 TRIAL

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

ClinicalTrials.gov

This is a Phase 3 trial registration with no results posted; the study is actively recruiting and has not yet reported efficacy or safety outcomes.

SEP 8, 2026 · PHASE 3 TRIAL

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

ClinicalTrials.gov

This is a clinical trial registry record describing a Phase 3 study that is currently recruiting with no results posted; it documents planned design and endpoints only.

AUG 20, 2026 · PHASE 2 TRIAL

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

ClinicalTrials.gov

Phase 2 trial with estimated enrollment of 36 participants testing a four-drug combination; no results are reported in this registry record.

AUG 19, 2026 · PHASE 3 TRIAL

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

ClinicalTrials.gov

This is a clinical trial registry record describing an active Phase 3 study with no results posted; the planned design is sound but efficacy and safety outcomes remain unreported.

AUG 18, 2026 · PHASE 2 TRIAL

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

ClinicalTrials.gov

This is a Phase 2, single-arm feasibility study with no results yet posted; it is designed to evaluate concurrent SBRT and immunotherapy but carries no outcome data to assess efficacy or safety.